Cryoablation of Small Breast Tumors in Early Stage Breast Cancer

Status: Active


This study examines the use of cryoablation as an alternative to surgery in the treatment of early stage invasive breast cancer. The hypothesis is that cryoablation will complete ablation and destroy the tumor in a selected population of women who may otherwise be adequately treated with surgery.

Eligibility Criteria

Inclusion Criteria

  • Age ≥ 50
  • Unifocal primary invasive breast carcinoma diagnosed by core needle biopsy
  • Maximum tumor size ≤1.5 cm in its greatest diameter
  • Ultrasound visible lesion(s)
  • Clinically node negative, hormone receptor positive (+). HER2 negative (-), with <25% intraductal component in the aggregate.
  • Unilateral or bilateral disease meeting study criteria
  • Physical and emotional ability to undergo baseline and follow-up breast MRIs and serial breast cosmesis analysis
  • Patient agrees to receive a 5 year minimum course of endocrine therapy following cryoablation for control of systemic disease

Exclusion Criteria

  • Prior treatment (e.g., open surgical biopsy, lumpectomy) of index cancer
  • Ductal carcinoma in-situ with microinvasions (T1mic)
  • Multifocal or multicentric invasive breast carcinoma
  • Prior or planned neoadjuvant systemic therapy for breast cancer
  • Tumor with ≥25% IDC components

Locations & Contacts


City of Hope Comprehensive Cancer Center
Status: Active
Name Not Available

Trial Objectives and Outline

PURPOSE: To determine the rate of successful tumor ablation in patients treated with cryoablation and endocrine therapy in a subset of patients with early stage breast cancer. OUTLINE: 1. Core Biopsy (Pre-Registration) 2. Magnetic Resonance Imaging (Pre-Registration) 3. Tumor Cryoablation 4. Core Biopsy (Post-Cryoablation) 5. Magnetic Resonance Imaging (Post-Cryoablation) 6. Postoperative Follow-up 7. Evaluation of outcomes

Trial Phase & Type

Trial Phase

No phase specified

Trial Type


Lead Organization

Lead Organization
Sanarus Technologies, Inc.

Trial IDs

Primary ID CP-00-0011
Secondary IDs NCI-2017-00241 ID NCT01992250